Mizuho reaffirmed their buy rating on shares of Celgene (NASDAQ:CELG) in a research note released on Wednesday morning. The brokerage currently has a $128.00 price target on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on the company. Morgan Stanley cut Celgene from an equal weight rating to an underweight rating and set a $120.00 target price for the company. in a research note on Thursday, October 5th. Sanford C. Bernstein cut Celgene from an outperform rating to a market perform rating and set a $121.00 target price for the company. in a research note on Wednesday, December 27th. BTIG Research reaffirmed a hold rating on shares of Celgene in a research note on Sunday, October 22nd. Cantor Fitzgerald reaffirmed a hold rating and set a $112.00 target price on shares of Celgene in a research note on Monday, October 30th. Finally, Vetr raised Celgene from a buy rating to a strong-buy rating and set a $144.39 target price for the company in a research note on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $129.98.

Celgene (NASDAQ CELG) traded down $0.30 during trading hours on Wednesday, hitting $101.72. The stock had a trading volume of 9,270,570 shares, compared to its average volume of 6,480,000. Celgene has a 12 month low of $94.55 and a 12 month high of $147.17. The company has a market capitalization of $80,090.00, a PE ratio of 23.99, a price-to-earnings-growth ratio of 0.67 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the prior year, the business posted $1.58 earnings per share. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. equities analysts expect that Celgene will post 6.7 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Thompson Davis & CO. Inc. raised its stake in shares of Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI raised its stake in shares of Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares in the last quarter. Robecosam AG purchased a new stake in shares of Celgene during the 3rd quarter worth about $114,000. Guidant Wealth Advisors purchased a new stake in shares of Celgene during the 3rd quarter worth about $119,000. Finally, Capital Bank & Trust Co raised its stake in shares of Celgene by 166.8% during the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 517 shares in the last quarter. 79.85% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/01/18/mizuho-reiterates-buy-rating-for-celgene-celg.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.